200 related articles for article (PubMed ID: 25516680)
21. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Hammel P; Huguet F; van Laethem JL; Goldstein D; Glimelius B; Artru P; Borbath I; Bouché O; Shannon J; André T; Mineur L; Chibaudel B; Bonnetain F; Louvet C;
JAMA; 2016 May; 315(17):1844-53. PubMed ID: 27139057
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Sudo K; Hara R; Nakamura K; Kita E; Tsujimoto A; Yamaguchi T
Cancer Chemother Pharmacol; 2017 Jul; 80(1):195-202. PubMed ID: 28597040
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
Ioka T; Furuse J; Fukutomi A; Mizusawa J; Nakamura S; Hiraoka N; Ito Y; Katayama H; Ueno M; Ikeda M; Sugimori K; Okano N; Shimizu K; Yanagimoto H; Okusaka T; Ozaka M; Todaka A; Nakamori S; Tobimatsu K; Sata N; Kawashima Y; Hosokawa A; Yamaguchi T; Miyakawa H; Hara H; Mizuno N; Ishii H;
Jpn J Clin Oncol; 2021 Feb; 51(2):235-243. PubMed ID: 33164066
[TBL] [Abstract][Full Text] [Related]
25. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Chabot JA; Tsai WY; Fine RL; Chen C; Kumah CK; Antman KA; Grann VR
J Clin Oncol; 2010 Apr; 28(12):2058-63. PubMed ID: 19687327
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
28. Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Nio Y; Hashimoto K; Yano S; Itakura M; Koike M; Yamaguchi K; Endo S; Tsuji M; Higami T; Maruyama R
Oncol Rep; 2005 Aug; 14(2):401-8. PubMed ID: 16012722
[TBL] [Abstract][Full Text] [Related]
29. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
Woo SM; Kim MK; Joo J; Yoon KA; Park B; Park SJ; Han SS; Lee JH; Hong EK; Kim YH; Moon H; Kong SY; Kim TH; Lee WJ
Cancer Res Treat; 2017 Oct; 49(4):1022-1032. PubMed ID: 28111423
[TBL] [Abstract][Full Text] [Related]
30. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Picozzi VJ; Ramanathan RK; Lowery MA; Ocean AJ; Mitchel EP; O'Neil BH; Guarino MJ; Conkling PR; Cohen SJ; Bahary N; Frank RC; Dragovich T; Bridges BB; Braiteh FS; Starodub AN; Lee FC; Gribbin TE; Richards DA; Lee M; Korn RL; Pandit-Taskar N; Goldsmith SJ; Intenzo CM; Sheikh A; Manzone TC; Horne H; Sharkey RM; Wegener WA; O'Reilly EM; Goldenberg DM; Von Hoff DD
Eur J Cancer; 2015 Sep; 51(14):1857-64. PubMed ID: 26187510
[TBL] [Abstract][Full Text] [Related]
31. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
[TBL] [Abstract][Full Text] [Related]
32. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Liu Y; Huang QK; Hong WD; Wu JM; Sun XC
Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193
[TBL] [Abstract][Full Text] [Related]
33. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Rocha Lima CM; Green MR; Rotche R; Miller WH; Jeffrey GM; Cisar LA; Morganti A; Orlando N; Gruia G; Miller LL
J Clin Oncol; 2004 Sep; 22(18):3776-83. PubMed ID: 15365074
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Ouyang G; Liu Z; Huang S; Li Q; Xiong L; Miao X; Wen Y
World J Surg Oncol; 2016 Feb; 14():59. PubMed ID: 26927942
[TBL] [Abstract][Full Text] [Related]
36. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
37. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
[TBL] [Abstract][Full Text] [Related]
38. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Von Hoff DD; Ervin T; Arena FP; Chiorean EG; Infante J; Moore M; Seay T; Tjulandin SA; Ma WW; Saleh MN; Harris M; Reni M; Dowden S; Laheru D; Bahary N; Ramanathan RK; Tabernero J; Hidalgo M; Goldstein D; Van Cutsem E; Wei X; Iglesias J; Renschler MF
N Engl J Med; 2013 Oct; 369(18):1691-703. PubMed ID: 24131140
[TBL] [Abstract][Full Text] [Related]
39. High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Chang JS; Wang ML; Koom WS; Yoon HI; Chung Y; Song SY; Seong J
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1448-54. PubMed ID: 22285669
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
